ArticleApplied biochemistry and biotechnology2026
Enhanced Anti-inflammatory Effects of 18β-Glycyrrhetinic Acid and Hesperetin for the Treatment of Psoriasis: Evidence from LPS-stimulated RAW264.7 Cells and Imiquimod-induced Psoriasis Mouse Model.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a persistent, immune-driven inflammatory skin disorder impacting an estimated 125 million individuals globally. The pursuit of effective and safe treatments at affordable costs remains an ongoing challenge. Phytochemicals show promise due to their anti-inflammatory and immunomodulatory effects. Phytochemicals 18β-glycyrrhetinic acid (GA) and hesperetin (HST) exhibit excellent anti-inflammatory properties in cells; however, their low oral bioavailability in the blood compromises their therapeutic potential. This study aimed to evaluate the combined effects of GA and HST in lipopolysaccharide (LPS)-stimulated RAW264.7 cells and an imiquimod (IMQ)-induced psoriasis mouse model. The results demonstrated that GA and HST synergistically inhibited nitric oxide production at a 1:1 concentration ratio in vitro. The combination also reduced IL-1β and IL-6 levels in LPS-stimulated RAW264.7 cells more effectively than either compound alone. Compared with either treatment alone, the combination of these two compounds significantly reduced the PASI scores, spleen index, Baker's histology score, and pro-inflammatory cytokines IL-1β, IL-6, IL-17, IL-22, IL-23, and TNF-α in the IMQ-induced psoriasis mouse model. Moreover, this combination also significantly upregulated the expression of the anti-inflammatory cytokine IL-10. The anti-psoriatic effects of this combination are comparable to the reference drug methotrexate. This research provides a rationale for the combination of GA and HST as an effective anti-psoriatic agent.
Indexed as
Identifiers
42821055What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.